BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets.

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results.

Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023.

Acadia Pharmaceuticals Inc. announced that on September 8, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,749 shares of common stock and 14,306 restricted stock units to 14 new employees under Acadia’s 2023 Inducement Plan.

Conduit Pharmaceuticals Limited and Murphy Canyon Acquisition Corp., a special purpose acquisition company (Nasdaq: MURF) (“MURF”), announced today the completion of the previously announced business combination (the “Transaction”).

University of Texas Medical Branch, Jamaica Hospital Medical Center and University of Chicago unveiled new impact data during the Pulmonary Embolism Symposium illustrating the importance of artificial intelligence in PE care.

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze ® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

Hillstream BioPharma Inc., announced a corporate name change to Tharimmune, Inc.

Alex Hamlow has joined Seno Medical Instruments, Inc. as Chief Revenue Officer. Seno Medical is the leader in improving the process of diagnosing breast cancer and the pioneer of the Imagio® Breast Imaging System with opto-acoustic/ultrasound (OA/US) imaging technology.